跳至主要内容
临床试验/NL-OMON55112
NL-OMON55112尚未招募3 期

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis - I1F-MC-RHCG

Eli Lilly and company0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
9

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 17(—)

入选标准

  • -Participants must have active juvenile idiopathic arthritis (categories of
  • XML File Identifier: Ie7xYHwCz5AAtrp51Ac/ZIiKACw=
  • enthesitis related arthritis or juvenile psoriatic arthritis)
  • Participants must have weight of at least 10 kilograms (Kg), age
  • starting at 2 years for participants with juvenile psoriatic arthritis and
  • starting at 6 years for participants with enthesitis related arthritis
  • Participants must have all immunizations up-to-date in agreement
  • with current immunization guidelines, in the opinion of the investigator

排除标准

  • - Participants must not have active or history of inflammatory bowel disease
  • ? Participants must not have active uveitis
  • ? Participants must not have active or latent tuberculosis
  • ? Participants must not have an active infection
  • ? Participants must not have concurrent use of biologic agents for the
  • treatment of the juvenile idiopathic arthritis

研究者

相似试验

进行中(未招募)
1 期
An Ixekizumab study with Adalimumab reference arm in children and young adults with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related ArthritisJuvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritisMedDRA version: 23.1Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2018-000681-10-BEEli Lilly and Company100
进行中(未招募)
1 期
An Ixekizumab study with Adalimumab reference arm in children and young adults with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related ArthritisJuvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritisMedDRA version: 21.0Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2018-000681-10-GBEli Lilly and Company100
进行中(未招募)
1 期
An Ixekizumab study with Adalimumab reference arm in children and young adults with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related ArthritisJuvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritisMedDRA version: 23.1Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2018-000681-10-DEEli Lilly and Company100
进行中(未招募)
1 期
An Ixekizumab study with Adalimumab reference arm in children and young adults with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related ArthritisJuvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritisMedDRA version: 23.1Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2018-000681-10-CZEli Lilly and Company100
进行中(未招募)
1 期
An Ixekizumab study with Adalimumab reference arm in children and young adults with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related ArthritisJuvenile Idiopathic Arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritisMedDRA version: 21.0Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2018-000681-10-FREli Lilly and Company100
Multicenter, Open-label, Efficacy, Safety,... | 临床试验